CTEP
CAS No. 871362-31-1
CTEP ( RO4956371; RO-4956371; RO 4956371; CTEP )
产品货号. M17635 CAS No. 871362-31-1
CTEP (RO4956371) is a novel, long-acting, orally bioavailable allosteric antagonist of mGlu5 receptor with IC50 of 2.2 nM, shows >1000-fold selectivity over other mGlu receptors.
纯度: 98%
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
规格 | 价格/人民币 | 库存 | 数量 |
2MG | ¥421 | 有现货 |
|
5MG | ¥656 | 有现货 |
|
10MG | ¥1150 | 有现货 |
|
25MG | ¥2017 | 有现货 |
|
50MG | ¥3645 | 有现货 |
|
100MG | ¥4957 | 有现货 |
|
500MG | ¥10692 | 有现货 |
|
1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称CTEP
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述CTEP (RO4956371) is a novel, long-acting, orally bioavailable allosteric antagonist of mGlu5 receptor with IC50 of 2.2 nM, shows >1000-fold selectivity over other mGlu receptors.
-
产品描述CTEP, also known as RO4956371, is a potent, long-acting, orally bioavailable allosteric antagonist of mGlu5 receptor with IC50 of 2.2 nM. CTEP binds mGlu5 with low nanomolar affinity and shows >1000-fold selectivity when tested against 103 targets, including all known mGlu receptors. CTEP penetrates the brain with a brain/plasma ratio of 2.6 and displaces the tracer ABP688 in vivo in mice from brain regions expressing mGlu5 with an average ED(50) equivalent to a drug concentration of 77.5 ng/g in brain tissue.
-
同义词RO4956371; RO-4956371; RO 4956371; CTEP
-
通路Endocrinology/Hormones
-
靶点5-HT Receptor
-
受体mGluR5
-
研究领域Neurological Disease
-
适应症——
化学信息
-
CAS Number871362-31-1
-
分子量391.77
-
分子式C19H13ClF3N3O
-
纯度98%
-
溶解度DMSO : ≥ 100 mg/mL. 255.25 mM; H2O : < 0.1 mg/mL
-
SMILESCC1=NC(C#CC2=CC=NC(Cl)=C2)=C(C)N1C1=CC=C(OC(F)(F)F)C=C1
-
化学全称2-chloro-4-[2-[2,5-dimethyl-1-[4-(trifluoromethoxy)phenyl]imidazol-4-yl]ethynyl]pyridine
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Lindemann L, et al. J Pharmacol Exp Ther, 2011, 339(2), 474-486.
产品手册
关联产品
-
Lurasidone hydrochlo...
Lurasidone is an atypical antipsychotic developed by Dainippon Sumitomo Pharma.
-
5-HT4 antagonist 1
5-HT4 antagonist 1 is an antagonist of 5-HT4 (pKi = 9.6).
-
Lafutidine
Lafutidine, a newly developed histamine H(2)-receptor antagonist, inhibits gastric acid secretion.